explore -WSS

explore

author：comprehensive 2025-09-03 07:36:20 - browse：9

IQVIA signage. -- health tech coverage from STAT — Adobe

The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： NYU radiologists take on the challenge of expensive MRI machines

WSS

FDA's Woodcock to retire early next year

Why palliative psychiatry is worth discussing

Antivenom research: Lessons from HIV applied in search for universal antidote

Ransomware attacks on hospitals: Study outlines patient impact

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

CRISPR pioneers react to Casgevy, first gene

Wikipedia

explore

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The Harvard botanist who searched for psychedelics in the Amazon

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Guidelines to prevent youth baseball injuries need more muscle

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Cancer drug shortages should be causing more outrage

Congress must reauthorize a committee to support older Americans

focus

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Gain of function research would be limited under House proposal

Does good food count as health care? Study aims to find out

Weight loss drug costs may need more research, senator suggests

With competition flaring, obesity drug hits goal in liver disease study

Astellas still sees hope in its gene therapy after four deaths

knowledge

hotspot

explore

entertainment